Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1879939 | 0.87 | PIK3CD (0.45) | PIK3CDNUDT1ADORA1DRD4DRD3 | |
| SCHEMBL1885076 | 0.83 | PIK3CD (0.42) | PIK3CDNUDT1DRD4DRD3L3MBTL1 | |
| SCHEMBL1888178 | 0.80 | PIK3CD (0.45) | PIK3CDDRD4DRD3L3MBTL1 | |
| SCHEMBL1884683 | 0.78 | PIK3CD (0.40) | PIK3CDNUDT1 | |
| SCHEMBL1887094 | 0.78 | PIK3CD (0.45) | PIK3CDDRD4DRD3L3MBTL1 | |
| SCHEMBL1881538 | 0.76 | NPC1 (0.42) | PIK3CDNUDT1ADORA1L3MBTL1GABRA5 | |
| SCHEMBL1884319 | 0.75 | PIK3CD (0.47) | PIK3CDDRD4DRD3L3MBTL1 | |
| SCHEMBL1883710 | 0.75 | DHFR (0.47) | — | |
| SCHEMBL1882523 | 0.74 | PIK3CD (0.40) | PIK3CDNUDT1ADORA1ADORA2A | |
| SCHEMBL1882298 | 0.73 | L3MBTL1 (0.49) | PIK3CDDRD4DRD3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | PIK3CD 8/4885NUDT1 1761/4885FFAR1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.